What the Trial Landscape Looks Like
The current asthma trial ecosystem in the U.S. is shaped by a few important realities. First, the shift toward precision medicine means many studies now screen for specific biomarkers (eosinophil counts, IgE levels, fractional exhaled nitric oxide) rather than simply accepting anyone with a diagnosis. This is good news for patients whose asthma has a clear inflammatory signature, but it also means the screening process can feel more involved than it did a decade ago.
Second, the rise of biologic therapies has changed the kinds of questions researchers ask. Instead of testing whether a new drug beats a placebo, many Phase III and Phase IV trials now compare biologics head-to-head, or examine whether patients on a biologic can safely reduce their inhaled corticosteroid dose. The TAPER study, sponsored by AstraZeneca, is doing exactly that — exploring whether tezepelumab-treated patients can step down their background medications without losing control.
Third, trial locations are concentrated in urban and suburban areas with large academic medical centers. Someone living in Tucson can walk into the University of Arizona Asthma and Airway Disease Research Center. A Chicago resident has Northwestern's Airways Disease Center. But for people in rural Montana or the Mississippi Delta, the nearest trial site might be a four-hour drive. Telemedicine components are appearing in some study designs, though they remain the exception, not the rule.
The types of trials actively recruiting in 2026 cover a broad spectrum. The table below captures the main categories a prospective participant might encounter.
| Trial Type | Example | Typical Duration | Ideal Candidate | Key Benefit | Considerations |
|---|
| Biologic (anti-TSLP, anti-IL-5, etc.) | Tezepelumab TAPER study | 12–24 months | Severe eosinophilic or T2-high asthma | Potential to reduce oral steroid dependence | Requires regular injections at a clinic |
| Novel oral therapy | TRIM (Roflumilast) | 6 months | Poorly controlled asthma with elevated BMI | Oral medication rather than injection | Gastrointestinal side effects possible |
| Inhaler combination | Fluticasone/Albuterol fixed-dose | 12–52 weeks | 12 years and older, history of exacerbations | Single inhaler for both maintenance and rescue | Requires strict adherence to diary keeping |
| Monoclonal antibody (new target) | GB-0895 (SOLAIRIA-2) | 12–18 months | Severe uncontrolled asthma on ICS/LABA | Access to a therapy years before FDA submission | Placebo-controlled design means 50% chance of inactive treatment |
| Pediatric-focused | CAUSE network studies | Varies | Children and adolescents in urban settings | Addresses environmental triggers like cockroach allergen | Parental involvement required for all visits |
How People Actually Find and Join a Trial
The process is not mysterious, but it does require patience. Most participants start with ClinicalTrials.gov, the National Institutes of Health registry that lists every federally and privately funded study in the country. Typing "asthma" and a city name into the search bar returns a list of recruiting trials, each with a "Contacts and Locations" section that includes a phone number or email address.
A growing number of people find trials through their own pulmonologists or allergists. Physicians affiliated with academic hospitals often know which studies are enrolling and can make a direct referral. This route saves time because the doctor has already confirmed that the patient's clinical profile roughly matches the inclusion criteria.
The American Lung Association maintains a dedicated clinical trials page with pre-screened listings from its ACRC network. These trials tend to be well-organized and patient-friendly, with clear explanations of what participation entails. The ALA's TRIM study, for instance, spells out the commitment: seven clinic visits over six months, breathing tests at each visit, two blood draws total, and a daily asthma diary.
Once a person contacts a study coordinator, the screening process begins. It typically involves a phone call to review medical history, followed by an in-person visit with lung function testing, blood work, and a detailed discussion of current medications. Some trials require a washout period during which participants stop certain drugs before the first dose of the study medication. This step can be physically uncomfortable, and coordinators monitor it carefully.
Eligibility criteria vary by study, but common requirements include a documented asthma diagnosis of at least 12 months, evidence of airway reversibility on spirometry, and a history of exacerbations despite using medium- or high-dose inhaled corticosteroids. Studies focused on severe asthma often look for an Asthma Control Questionnaire score (ACQ-5) of 1.5 or higher. Some trials, like the NIOSH-funded study for World Trade Center responders with asthma at Mount Sinai, have very specific occupational or exposure-related criteria.
Compensation, Costs, and What Gets Covered
One of the most common questions people ask is whether they will be paid. The answer is yes, most trials provide compensation, but the amount varies widely and is structured as reimbursement for time and travel rather than payment for risk. A screening visit alone might offer up to $125 for a few hours of testing, as seen in the University of Virginia's asthma protocol. Full study participation over several months can bring compensation that covers transportation, parking, meals during long visits, and the inconvenience of repeated clinic trips.
More significant than the stipend is what participants do not pay. The study drug, all lab work, spirometry, and specialist visits are covered by the trial sponsor. For someone whose insurance has a high deductible or who struggles with biologic copays that can run into hundreds of dollars monthly, this financial relief matters. Asthma biologics on the U.S. market carry annual list prices that can reach into the tens of thousands of dollars. A trial offers access to these same categories of medication — or newer versions of them — at no out-of-pocket cost.
That said, participants should clarify what is not covered before signing the consent form. Routine asthma care that falls outside the study protocol, emergency room visits for exacerbations, and medications prescribed by the participant's regular doctor generally remain the patient's responsibility. Some trials have provisions for covering urgent care related to the study, but this varies.
Weighing the Decision
The decision to join a trial is personal and rarely straightforward. On one side sits the possibility of accessing a treatment that works better than anything currently available. On the other sits the uncertainty of an investigational drug — the side effects that might not yet be documented, the chance of being randomized to a placebo arm, the hours spent in clinic visits that could otherwise go to work or family.
A 34-year-old teacher in Houston with moderate persistent asthma might find that a Phase III inhaler combination study fits her life. The commitment is manageable, the drug class is familiar, and the monitoring provides reassurance. A 52-year-old construction worker in Chicago with severe, uncontrolled asthma might consider a biologic trial because his current regimen leaves him breathless climbing a single flight of stairs. The potential benefit outweighs the inconvenience of biweekly injections.
Then there are parents like the Johnsons in Tucson, whose 12-year-old daughter has allergic asthma triggered by the desert pollen season. A pediatric trial through the University of Arizona's center could mean closer monitoring than a standard pediatrician visit provides, plus access to therapies studied specifically in children rather than extrapolated from adult data.
The research teams running these studies understand the hesitation. They are accustomed to questions about placebo arms, about what happens when the trial ends, about whether participants can continue the study drug if it works. The informed consent document, while lengthy, is designed to answer these questions in writing before any commitment is made.
For anyone considering this path, the first step is straightforward: search ClinicalTrials.gov with the terms "asthma" and your state, or call the nearest academic medical center's pulmonary department and ask whether they are recruiting. The ALA's clinical trials page (lung.org/research/clinical-trials) offers another entry point with pre-vetted studies. A conversation with a study coordinator carries no obligation. It simply tells you whether your asthma profile matches what researchers are looking for — and whether the trial might be worth the time.
研究の知恵